Fulgent Genetics (NASDAQ:FLGT) COO Jian Xie Sells 2,127 Shares of Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 2,127 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.66, for a total value of $41,816.82. Following the transaction, the chief operating officer directly owned 359,924 shares of the company’s stock, valued at approximately $7,076,105.84. This trade represents a 0.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jian Xie also recently made the following trade(s):

• On Thursday, August 27th, Jian Xie sold 1,193 shares of Fulgent Genetics stock. The stock was sold at an average price of $19.91, for a total transaction of $23,752.63.

Fulgent Genetics Stock Down 1.9%

NASDAQ FLGT opened at $19.65 on Friday. Fulgent Genetics, Inc. has a 12-month low of $13.46 and a 12-month high of $31.04. The company has a market capitalization of $540.57 million, a PE ratio of -6.97 and a beta of 0.93. The firm’s 50 day moving average is $19.71 and its 200-day moving average is $18.01.

Fulgent Genetics (NASDAQ:FLGT) last announced its earnings results on Thursday, July 30th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.12). The business had revenue of $85.39 million for the quarter, compared to analyst estimates of $94.00 million. Fulgent Genetics had a negative return on equity of 4.93% and a negative net margin of 26.05%.Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. As a group, sell-side analysts expect that Fulgent Genetics, Inc. will post -3.48 EPS for the current year.

Wall Street Analyst Weigh In

FLGT has been the topic of a number of recent research reports. Wall Street Zen raised Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Weiss Ratings upgraded Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Finally, Piper Sandler raised their price target on Fulgent Genetics from $15.00 to $19.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $27.50.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC lifted its holdings in Fulgent Genetics by 69.3% during the 4th quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock valued at $35,000 after purchasing an additional 548 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of Fulgent Genetics by 1.2% in the fourth quarter. Federated Hermes Inc. now owns 47,102 shares of the company’s stock valued at $1,237,000 after purchasing an additional 552 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Fulgent Genetics by 2.4% in the second quarter. Rhumbline Advisers now owns 33,139 shares of the company’s stock valued at $659,000 after purchasing an additional 785 shares during the last quarter. Swiss National Bank raised its position in shares of Fulgent Genetics by 3.2% in the fourth quarter. Swiss National Bank now owns 39,200 shares of the company’s stock valued at $1,030,000 after purchasing an additional 1,200 shares during the period. Finally, Allworth Financial LP bought a new position in shares of Fulgent Genetics in the second quarter valued at about $25,000. 48.06% of the stock is owned by institutional investors and hedge funds.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.